Do you want to read an article? Please log in or register.
Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients
Lipid-Lowering Drugs
Related content
Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesLipid-Lowering Drugs
Alirocumab Treatment and Achievement of Non-High-Density Lipoprotein Cholesterol and Apolipoprotein B Goals in Patients With Hypercholesterolemia: Pooled Results From 10 Phase 3 ODYSSEY Trials
J Am Heart Assoc.
Bays HE, Leiter LA, Colhoun HM, Thompson D, Bessac L, Pordy R, Toth PP
doi: 10.1161/JAHA.117.005639.
Lipid-Lowering DrugsTherapy and Intervention
Clinical Efficacy and Safety of Evolocumab in High-Risk Patients Receiving a Statin: Secondary Analysis of Patients With Low LDL Cholesterol Levels and in Those Already Receiving a Maximal-Potency Statin in a Randomized Clinical Trial
JAMA Cardiol.
Giugliano RP, Keech A, Murphy SA, Huber K, Tokgozoglu SL, Lewis BS, Ferreira J, Pineda AL, Somaratne R, Sever PS, Pedersen TR, Sabatine MS
doi: 10.1001/jamacardio.
Cardiovascular Risk and Diseases
Application of non-HDL cholesterol for population-based cardiovascular risk stratification: results from the Multinational Cardiovascular Risk Consortium
Lancet.
Brunner FJ, Waldeyer C, Ojeda F, Salomaa V, Kee F, Sans S, Thorand B, Giampaoli S, Brambilla P, Tunstall-Pedoe H, Moitry M, Iacoviello L, Veronesi G, Grassi G, Mathiesen EB, Söderberg S, Linneberg A, Brenner H, Amouyel P, Ferrières J, Tamosiunas A, Nikitin YP, Drygas W, Melander O, Jöckel KH, Leistner DM, Shaw JE, Panagiotakos DB, Simons LA, Kavousi M, Vasan RS, Dullaart RPF, Wannamethee SG, Risérus U, Shea S, de Lemos JA, Omland T, Kuulasmaa K, Landmesser U, Blankenberg S, Multinational Cardiovascular Risk Consortium.
doi: 10.1016/S0140-6736(19)32519-X.
Cardiovascular Risk and DiseasesLipid-Lowering DrugsMyocardial InfarctionThrombosis and StrokeTherapy and Intervention
Residual Inflammatory Risk On Treatment with PCSK9 Inhibition and Statin Therapy
Circulation.
Pradhan AD, Aday AW, Rose LM, Ridker PM
doi: 10.1161/CIRCULATIONAHA.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Evolocumab on Non-High-Density Lipoprotein Cholesterol, Apolipoprotein B, and Lipoprotein(a): A Pooled Analysis of Phase 2 and Phase 3 Studies
★ 2
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
J Am Heart Assoc.
Toth PP, Jones SR, Monsalvo ML, Elliott-Davey M, López JAG, Banach M
doi: 10.1161/JAHA.119.014129.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials
Eur Heart J.
Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Räber L, Mach F, Windecker S
doi: 10.1093/eurheartj/ehx566.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High-Risk Vascular Disease Treated With Statin Therapy
J Am Heart Assoc.
Menon V, Kumar A, Patel DR, John JS, Wolski KE, McErlean E, Riesmeyer JS, Weerakkody G, Ruotolo G, Cremer PC, Nicholls SJ, Lincoff AM, Nissen SE
doi: 10.1161/JAHA.119.014328.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
N Engl J Med.
Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ
doi: 10.1056/NEJMoa1615758.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA.
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB
doi: 10.1001/jama.2019.16585.